Medexus Pharmaceuticals (MDP) Stock Price, News & Analysis

Company Overview

Medexus Pharmaceuticals Inc, formerly Pediapharm Inc is a leading specialty pharmaceutical company with a strong North American commercial platform. It is focused on the therapeutic areas of auto-immune disease and pediatrics. The leading products are Rasuvo and Metoject, a unique formulation of methotrexate to treat rheumatoid arthritis and other auto-immune diseases; and Rupall, an innovative allergy medication with a unique mode of action.

Key Stats

• Today's Range: C$2.89 to C$3.12
• 50-Day Range: C$2.50 to C$3.40
• 52-Week Range: C$1.71 to C$5.56
• Volume: 24,029 shs
• Average Volume: 78,828 shs
• Market Capitalization: C$65.60 million
• P/E Ratio: 14.01
• Dividend Yield: N/A
• Price Target: C$5.49
• Consensus Rating: Buy

MDP Stock Analysis - Frequently Asked Questions

How have MDP shares performed this year?

Medexus Pharmaceuticals' stock was trading at C$3.46 on January 1st, 2025. Since then, MDP shares have decreased by 15.3% and is now trading at C$2.93.

How do I buy shares of Medexus Pharmaceuticals?

Shares of MDP stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.

What other stocks do shareholders of Medexus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Medexus Pharmaceuticals investors own include AutoZone (AZO), Cisco Systems (CSCO), Facedrive (FDVRF), Intel (INTC), kneat.com (KSI), NIO (NIO) and Nanotech Security (NTS).

Industry, Sector and Symbol

• Stock Exchange: TSE
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: N/A
• Current Symbol: TSE:MDP
• CIK: N/A
• Web: www.medexus.com
• Phone: 877-633-3987
• Fax: N/A
• Employees: 98
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Medexus Pharmaceuticals: C$5.49
• High Price Target: C$8.25
• Low Price Target: C$3.45
• Potential Upside/Downside: +87.3%
• Consensus Rating: Buy
• Rating Score (0-4): 3.29
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): C$0.21
• Trailing P/E Ratio: 14.01
• Forward P/E Ratio: 17.94
• P/E Growth: N/A
• Net Income: C$3.26 million
• Net Margins: 3.25%
• Pretax Margin: N/A
• Return on Equity: 11.07%
• Return on Assets: 4.89%

Debt

• Debt-to-Equity Ratio: 120.58
• Current Ratio: 1.01
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: C$100.25 million
• Price / Sales: 0.65
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: C$1.35 per share
• Price / Book: 2.17

Miscellaneous

• Outstanding Shares: 22,388,156
• Free Float: N/A
• Market Cap: C$65.60 million
• Optionable: Not Optionable
• Beta: 1.96